RFA-AR-25-013-Full-Announcement.html

The file represents a Request for Application (RFA) for the Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies, a U01 clinical trial cooperative agreement. The funding opportunity is issued by the Department of Health and Human Services National Institutes of Health, specifically the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and will leverage remaining funds from the 21st Century Cures Act. The grant is currently in a forecast stage, with applications not yet being solicited, allowing potential applicants time to develop collaborations and responsive projects.

The opportunity is associated with multiple federal grant programs, including Arthritis, Musculoskeletal and Skin Diseases Research (CFDA 93.846), Lung Diseases Research (CFDA 93.838), Cardiovascular Diseases Research (CFDA 93.837), and Translation and Implementation Science Research (CFDA 93.840). While specific award values are not detailed in this document, the related federal grant programs typically fund projects ranging from $30,000 to over $1 million, with project periods spanning 1-5 years. The notice specifically encourages previously funded Regenerative Medicine Innovation Project investigators to consider applying for this new Notice of Funding Opportunity, with a focus on advancing research using adult stem cells.